Legend Biotech shares tumble as Carvykti outlook overshadows profit
Cancer treatment developer Legend Biotech Corp. (LEGN.US) reported on Tuesday that its third-quarter revenue rose 32% year-on-year to $359.5 million, while its net income reached $51.7 million, reversing a $39.6…
Legend Biotech names new CEO
Cancer treatment maker Legend Biotech Corp. (LEGN.US) announced its appointment of a new CEO on Tuesday, a month and a half after the sudden departure of its longtime chief executive…
Legend Bio CEO resigns, shares tumble
Drugmaker Legend Biotech Corp. (LEGN.US) said on Monday that Huang Ying resigned as the company’s CEO and member of its board effective July 24, without giving any reason for his departure.…
BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment
Drug developer Legend Biotech Corp. (LEGN.US) on Tuesday reported its revenue rose 56% year-on-year to $305.1 million in the first quarter, as it reaped the benefit of strong sales for…
BRIEF: Legend Biotech posts strong fourth-quarter revenue gain
Legend Biotech Corp. (LEGN.US) on Tuesday reported strong double-digit revenue growth in last year’s fourth quarter on solid gains for its core Carvykti cancer treatment, lifting the company to a…
BRIEF: Legend Biotech considers second listing outside U.S.
Cancer treatment maker Legend Biotech Corp. (LEGN.US) is weighing a second listing to complement its existing one in the U.S., with possible venues including Hong Kong, Singapore and London, Bloomberg…
BRIEF: Legend Biotech’s revenue rises 36% in second quarter
Drug maker Legend Biotech Corp. (LEGN.US) on Monday reported strong revenue growth in the second quarter of 2025 as its core cancer drug gained traction. But its net loss also…
